This is a summary of the European public assessment report (EPAR) for Lyxumia. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lyxumia.
Therapeutic Indication
### Therapeutic indication Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
Therapeutic Area (MeSH)
ATC Code
A10BJ03
ATC Item
lixisenatide
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| lixisenatide | N/A | 利司那肽 |
EMA Name
Lyxumia
Medicine Name
Lyxumia
Aliases
N/ANo risk management plan link.
